Comparing the current results to its competitors, Illumina Inc reported Revenue increase in the 2 quarter 2026 by 9.44 % year on year. The revenue growth was below Illumina Inc 's competitors' average revenue growth of 11.44 %, achieved in the same quarter.
Illumina Inc 's Comment on Competition and Industry Peers
The company operates in the sequencing, SNP genotyping, gene expression, proteomics, and molecular diagnostics markets, where it faces intense competition. Competitors provide products, services, and software that may directly compete with or complement the company's offerings. Some competitors possess significantly greater financial, technical, research, and artificial intelligence capabilities, as well as larger marketing, sales, distribution, and service organizations, greater name recognition, and larger installed bases. The company anticipates the emergence of new competitors and increased competition.
Standard Biotools Inc operates as a biotechnology company that specializes in the development and distribution of standard laboratory tools and reagents. They offer a diverse range of high-quality products including lab equipment, molecular diagnostics, and research reagents to meet the needs of scientists and researchers in the life sciences industry. With a customer-centric approach, Standard Biotools aims to provide reliable and affordable solutions to support advancements in scientific research and discovery.
Pacific Biosciences Of California Inc Share Performance
-3.57%
Over The Past 5 Days
Pacific Biosciences Of California Inc
Profile
Pacific Biosciences of California Inc's business model revolves around the development and commercialization of innovative sequencing systems that enable scientists and researchers to study the complexity of biology. They provide high-resolution genetic analysis solutions, offering a comprehensive platform that includes consumables, systems, and data analysis software to support genomic analysis.
Prenetics Global Limited is a company that operates in the field of personalized healthcare by offering genetic testing services to individuals. The company partners with healthcare providers and insurance companies to provide insights and recommendations based on genetic information, aiming to empower individuals to make informed decisions about their health.
Sources:
Illumina Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Illumina Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
